ArticleJournal of clinical laboratory analysis2022
Constructing an immune- and ferroptosis-related lncRNA signature to predict the immune landscape of human bladder cancer.
Article in Journal of clinical laboratory analysis, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
9 citing papers in PubMed.
- Integrated Ferroptosis and Immune Features Are Associated With Overall Survival in Bladder Urothelial Carcinoma: A TCGA-Based Analysis.Cancer informatics · 2026Article
- Identification and single-cell analysis of prognostic genes related to mitochondrial and neutrophil extracellular traps in bladder cancer.Scientific reports · 2025Article
- Ferroptosis-related LncRNAs in diseases.BMC biology · 2025Review
- A redox-related lncRNA signature in bladder cancer.Scientific reports · 2024Article
- Mechanisms of ferroptosis and targeted therapeutic approaches in urological malignancies.Cell death discovery · 2024Review
- Ferroptosis: An Emerging Target for Bladder Cancer Therapy.Current issues in molecular biology · 2023Review
- Constructing an immune- and ferroptosis-related lncRNA signature to predict the immune landscape of human bladder cancer.Journal of clinical laboratory analysis · 2022Article
- Molecular subtypes and a prognostic model for hepatocellular carcinoma based on immune- and immunogenic cell death-related lncRNAs.Frontiers in immunology · 2022Article
- Ferroptosis: A new therapeutic target for bladder cancer.Frontiers in pharmacology · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
backgroundLncRNAs play a variety of roles in the tumor microenvironment and cancer immune responses. Determining the significance of bladder cancer (BLCA)-related genes to predict the prognostic and therapeutic response of BLCA is important.
methodsIrlncRNA/ frlncRNA pairs were determined using univariate analysis. The signature was constructed based on this pairs. Finally, analysis and internal validation were performed from several aspects.
resultsWe identified 60 immune- and ferroptosis-related lncRNA pairs, among which 12 were included in the Cox proportional hazards model. Patients in low-risk group survived for significantly longer. Survival and riskScore analyses showed that the low-risk group had a significantly better clinical outcome. ROC curve analysis showed that AUC of OS values were more than 0.75 in the training set and the whole cohort. As assessed using Cox analysis, the riskScore was an independent prognostic predictor in the training, testing set and the whole cohort. The areas under the multi-index ROC in the training set, the testing set, and the whole cohort were 0.777, 0.692, and 0.748, respectively. High-risk group was positively associated with most of tumor-infiltrating immune cells. High-risk Scores correlated positively with high expression of CD274, but not with PD-1. Low riskScores correlated positively with high expression levels of the genes ERBB2 and nectin-4. High-risk Score was associated with a lower IC50 value for Docetaxel, cisplatin, and Pazopanib, while there was an opposite result for metformin.
conclusionsThe signature constructed by pairing irlncRNAs and frlncRNAs showed a notable clinical predictive value.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.